ASO Therapy for Parkinson's Disease
Introduction
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ASO Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Description</td>
</tr>
<tr>
<td class="label">RNase H-mediated degradation</td>
<td>ASO-DNA-RNA hybrid recruits RNase H to cleave the mRNA</td>
</tr>
<tr>
<td class="label">Splicing modulation</td>
<td>ASO alters pre-mRNA splicing to reduce toxic isoforms</td>
</tr>
<tr>
<td class="label">Translational blockade</td>
<td>ASO blocks ribosome assembly on mRNA</td>
</tr>
<tr>
<td class="label">RNA interference</td>
<td>siRNA-loaded nanoparticles</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LRRK2 ASO</td>
<td>Ionis/partner</td>
</tr>
<tr>
<td class="label">GBA ASO</td>
<td>Various</td>
</tr>
<tr>
<td class="label">SNCA splicing modulators</td>
<td>Research labs</td>
</tr>
<tr>
<td class="label">Parkin ASO</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">System</td>
<td>Potential Adverse Events</td>
</tr>
<tr>
<td class="label">Neurological</td>
<td>Headache, back pain, dizziness</td>
</tr>
<tr>
<td class="label">Injection-related</td>
<td>Lumbar puncture syndrome, spinal headache</td>
</tr>
<tr>
<td class="label">Hematological</td>
<td>Platelet changes, liver enzyme elevations</td>
</tr>
<tr>
<td class="label">Immunogenic</td>
<td>Immune response to ASO</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>Reduce SNCA mRNA</td>
</tr>
<tr>
<td class="label">[Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy)</td>
<td>Antibody-mediated clearance</td>
</tr>
<tr>
<td class="label">[Aggregation inhibitors](/therapeutics/alpha-synuclein-aggregation-inhibitors)</td>
<td>Prevent fibril formation</td>
</tr>
<tr>
<td class="label">[Gene therapy](/therapeutics/aadc-gene-therapy)</td>
<td>Express therapeutic protein</td>
</tr>
</table>
Antisense oligonucleotide (ASO) therapy for Parkinson's Disease (PD) represents a promising disease-modifying strategy that aims to reduce the expression of [alpha-synuclein](/proteins/alpha-synuclein) (encoded by the [SNCA](/genes/snca) gene), a protein central to PD pathogenesis["@vercruysse2023"]. By targeting the root cause of alpha-synuclein aggregation, ASO therapy offers the potential to slow or halt disease progression rather than merely managing symptoms["@cooper2022"]. This therapeutic approach has garnered significant attention from both academic researchers and pharmaceutical companies, particularly following the success of ASO therapies in other neurological conditions such as spinal muscular atrophy (SMA) and Huntington's disease["@bennett2024"].
Parkinson's disease affects approximately 10 million people worldwide, making it the second most common neurodegenerative disease after Alzheimer's disease["@dorsey2023"]. The characteristic motor symptoms—resting tremor, bradykinesia, rigidity, and postural instability—result from the progressive loss of dopaminergic [neurons](/entities/neurons) in the substantia nigra pars compacta. While symptomatic treatments such as levodopa and deep brain stimulation have improved quality of life for millions of patients, there remains an urgent need for therapies that can modify the underlying disease process["@kalia2015"].
Mechanism of Action
Alpha-Synuclein Reduction Strategy
ASOs for PD are designed to bind to [SNCA](/genes/snca) mRNA transcripts through base-pairing complementarity, preventing their translation into alpha-synuclein protein[@vercruysse2023]. The therapeutic rationale is based on the well-established role of alpha-synuclein in PD pathogenesis:
- Lewy body formation: Alpha-synuclein aggregates are the primary component of Lewy bodies, a hallmark of PD pathology that was first described by Friedrich Lewy in 1912[@spillantini1997]
- Toxic gain-of-function: Misfolded alpha-synuclein exhibits prion-like properties, spreading throughout the nervous system in a manner similar to other protein aggregation diseases[@brundin2017]
- Dopaminergic neuron vulnerability: Alpha-synuclein toxicity particularly affects substantia nigra pars compacta dopamine neurons, leading to the characteristic motor deficits in PD[@dauer2003]
The choice of SNCA as a target reflects decades of genetic and pathological research establishing its central role in PD. Studies have shown that individuals with SNCA gene duplications or triplications develop parkinsonism, demonstrating that increased alpha-synuclein expression is sufficient to cause disease[@devine2011]. Conversely, reduced SNCA expression in humans (carrying loss-of-function mutations) appears to be protective against PD[@federoff2022].
ASO Mechanism Types
ASOs can employ several distinct mechanisms to reduce target gene expression, each with different pharmacological properties[@bennett2024]:
The RNase H-dependent mechanism is the most advanced for SNCA targeting. These ASOs are single-stranded DNA molecules (typically 12-20 nucleotides) that form DNA-RNA hybrids with target mRNA. RNase H recognizes these hybrids and cleaves the RNA strand, leading to mRNA degradation while the ASO is recycled for additional binding events[@bennett2024].
Pharmacodynamic Considerations
The goal of ASO therapy for PD is to achieve partial rather than complete SNCA knock-down[@cooper2022]:
- Therapeutic window: Complete elimination of alpha-synuclein may be detrimental, as the protein has normal physiological functions in synaptic vesicle regulation, neurotransmitter release, and neuronal plasticity[@burre2015]
- Target reduction: Preclinical studies suggest 30-50% reduction may be sufficient to slow disease progression while maintaining sufficient alpha-synuclein for normal neuronal function[@cooper2022]
- CSF biomarkers: Phosphorylated alpha-synuclein (pSer129) and total alpha-synuclein in cerebrospinal fluid serve as pharmacodynamic markers to monitor target engagement[@mollenhauer2023]
The selection of appropriate dose and dosing interval requires careful balance. Excessive reduction could lead to undesired effects on synaptic function, while insufficient reduction may not provide therapeutic benefit. Non-human primate studies have demonstrated that intrathecal ASO administration can achieve 40-60% reduction in CSF alpha-synuclein without significant adverse effects[@southwell2022].
Clinical Development
Ionis/Biogen Program: IONIS-SNAS (BIIB101)
The lead ASO program for PD was developed by Ionis Pharmaceuticals in collaboration with Biogen under the name IONIS-SNAS, later designated BIIB101[@biogen2022]:
Development Timeline
- Preclinical phase (2015-2019): Demonstrated dose-dependent SNCA reduction in rodent and non-human primate models, establishing proof-of-concept for CNS delivery[@mcgrew2020]
- Phase 1 (2019-2020): First-in-human study to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers
- Phase 1b/2a (2020-2022): Dose-escalation study in patients with Parkinson's disease to assess safety and preliminary efficacy[@biogen2022]
Trial Design
- Route: Intrathecal (lumbar puncture) administration
- Dosing: Multiple ascending doses, with patients receiving multiple injections over several months
- Endpoints: Safety, tolerability, CSF SNCA protein levels, pharmacokinetics, and exploratory clinical endpoints[@biogen2022]
The trial enrolled patients with moderate PD (Hoehn and Yahr stage 2-3) who were on stable dopaminergic therapy. This population was chosen because they had established alpha-synuclein pathology but retained sufficient dopaminergic neurons for potential therapeutic benefit.
Trial Outcomes
The Phase 1/2 study showed that BIIB101 was generally well-tolerated with no major safety concerns[@biogen2022]. Common adverse events included headache and mild injection-site reactions, consistent with other intrathecal ASO programs. However, Biogen discontinued the program in 2023 after determining it did not meet criteria for advancement to later-stage trials. The decision was reportedly based on insufficient target engagement or efficacy signals observed in the clinical trial data[@biogen2023].
The discontinuation highlighted several key challenges in ASO development for PD:
CNS distribution: Intrathecal delivery may not achieve uniform distribution throughout the brain regions most affected by alpha-synuclein pathology
Biomarker correlation: CSF alpha-synuclein may not accurately reflect target engagement in brain tissue
Disease staging: Patients with established disease may have already suffered irreversible neuronal lossOther ASO Programs
Following the Biogen decision, several other ASO programs targeting PD-relevant genes remain in various stages of development[@bennett2024]:
LRRK2 ASO: Gain-of-function mutations in LRRK2 are the most common genetic cause of familial PD, accounting for 5-10% of cases. ASO therapy targeting LRRK2 mRNA could benefit both familial and sporadic PD patients by reducing kinase activity that contributes to neuronal dysfunction[@alessi2018].
GBA ASO: Heterozygous mutations in GBA (glucocerebrosidase) are the most significant genetic risk factor for PD, increasing risk by approximately 5-fold. ASOs targeting GBA could reduce the production of abnormal glucocerebrosidase that leads to alpha-synuclein accumulation in lysosomes[@sidransky2009].
Lessons Learned
The discontinuation of the Biogen program provided valuable insights for future ASO development[@biogen2023]:
BBB penetration: Intrathecal delivery may not achieve uniform distribution throughout the brain; newer conjugate technologies are needed
Biomarker validation: CSF alpha-synuclein may not accurately reflect target engagement in brain tissue; alternative biomarkers are needed
Patient selection: Future trials may benefit from enriching for patients with elevated alpha-synuclein pathology or those in earlier disease stages
Delivery optimization: Newer conjugate approaches (antibody-ASO, peptide-ASO) may improve CNS distributionDelivery Methods
Intrathecal Administration
The current standard for CNS-targeted ASOs involves intrathecal administration via lumbar puncture[@bennett2024]:
- Procedure: Injection of ASO into cerebrospinal fluid in the lumbar region
- Distribution: Diffuses through CSF to reach spinal cord and some brain regions, with concentrations decreasing with distance from injection site
- Limitations: Invasive procedure requiring repeated lumbar punctures; uneven brain distribution; risk of infection or spinal headache
- Frequency: Typically monthly or quarterly dosing, depending on ASO pharmacokinetics
Intrathecal delivery has been validated in multiple FDA-approved ASO therapies for neurological diseases, including nusinersen for SMA and inotersen for hereditary transthyretin amyloidosis[@bennett2024]. However, the distribution characteristics of intrathecal ASOs may be particularly challenging for PD, where the substantia nigra and other deep brain structures are the primary therapeutic targets.
Emerging Delivery Strategies
New delivery technologies are being developed to overcome the limitations of intrathecal administration[@hammond2021]:
Conjugate Approaches
- Antibody-ASO conjugates: Engineer ASOs to cross the [blood-brain barrier](/entities/blood-brain-barrier) via receptor-mediated transcytosis, using antibodies against transferrin receptor or other BBB-crossing targets
- Cell-penetrating peptides (CPPs): Enhance cellular uptake and endosomal escape through incorporation of peptide sequences derived from HIV TAT protein or other transduction domains
- Aptamer-mediated delivery: Select aptamers that bind to specific receptors on brain endothelial cells to enable receptor-mediated transport
Alternative Routes
- Intravenous with BBB-crossing technology: If successful, would greatly improve patient convenience and enable chronic dosing
- Intranasal delivery: Direct nose-to-brain route under investigation, potentially offering rapid onset with minimal systemic exposure
- Focused ultrasound: Temporary BBB opening using focused ultrasound waves to enhance ASO penetration into specific brain regions[@burgess2024]
Safety Considerations
Adverse Events Profile
Based on the Ionis/Biogen trial and other CNS ASO programs, the safety profile is generally favorable[@biogen2022]:
The safety data from other CNS ASO programs (nusinersen, tofersen, inotersen) suggest that long-term treatment is generally well-tolerated, with most adverse events being mild to moderate in severity[@bennett2024].
Long-term Safety Concerns
Several theoretical long-term safety concerns require ongoing monitoring[@chi2023]:
- Off-target effects: ASOs may bind to unintended mRNA sequences with partial complementarity, potentially leading to unintended gene silencing
- Accumulation: Repeated dosing may lead to tissue accumulation in the CNS or peripheral organs
- CNS inflammation: Potential for neuroinflammation with chronic dosing, though clinical data to date have not shown significant inflammatory responses
- SNCA reduction safety: The long-term effects of sustained partial alpha-synuclein depletion are unknown; animal studies suggest tolerance but human data are limited
Risk Mitigation Strategies
Pharmaceutical companies employ multiple strategies to enhance ASO safety[@bennett2024]:
Careful sequence design: Extensive bioinformatics to minimize off-target binding, with screening against the entire transcriptome
Dose titration: Start low and escalate to find minimum effective dose that achieves target reduction
3.Biomarker monitoring**: Regular CSF and blood tests to assess safety signals and target engagement
Patient selection: Exclude patients at risk for complications (coagulopathy, spinal abnormalities, infection)Current Status and Future Outlook
2025-2026 Landscape
Following the discontinuation of the Biogen program, ASO therapy for PD remains in earlier developmental stages but continues to generate significant research interest[@biogen2023]:
- Academic research: Active investigation of next-generation ASO designs, including allele-selective oligonucleotides and modified chemistries
- Alternative targets: LRRK2, GBA, and other genetic targets remain of interest, with some programs advancing toward clinical development
- Combination approaches: ASO therapy combined with other disease-modifying strategies such as immunotherapy or aggregation inhibitors
The field is also benefiting from advances in other ASO programs targeting CNS diseases. The approval of tofersen for SOD1-ALS in 2023 demonstrated that ASOs can achieve meaningful clinical benefit in neurodegenerative diseases, providing a template for PD development[@fda2023].
Challenges and Opportunities
Key Challenges
Delivery: Achieving adequate brain penetration without invasive procedures remains the primary obstacle
Efficacy validation: Demonstrating disease modification in human trials requires long-term studies with appropriate endpoints
Biomarker development: Better markers for target engagement and disease progression are needed
Patient stratification: Identifying patients most likely to respond to therapy based on genetic background and disease stageOpportunities
Genetic PD subtypes: Patients with SNCA multiplications or mutations may benefit most from SNCA-targeted ASO[@devine2011]
Combination therapy: ASO with alpha-synuclein immunotherapy or aggregation inhibitors could provide complementary mechanisms
Personalized medicine: Genotype-guided ASO selection based on LRRK2, GBA, or other genetic variants
Prevention trials: ASO therapy in prodromal PD or high-risk populations could prevent disease onsetComparison with Other Disease-Modifying Approaches
Conclusion
ASO therapy for Parkinson's Disease represents a scientifically rational approach to disease modification by directly targeting the production of toxic alpha-synuclein. While the Ionis/Biogen program demonstrated the feasibility of ASO delivery to the CNS and established a safety database, the discontinuation of this program highlights the significant challenges remaining in this field[@biogen2023].
The path forward requires addressing several critical gaps:
- Improved delivery technologies that achieve robust brain distribution, particularly to deep brain structures
- Validated biomarkers that accurately reflect target engagement and predict clinical outcomes
- Careful patient selection to identify those most likely to benefit from therapy
- Combination approaches that address multiple aspects of PD pathogenesis
Despite these challenges, ASO therapy remains a promising modality in the Parkinson's disease therapeutic pipeline. The success of ASO platforms in other neurological diseases provides a strong foundation, and ongoing research into alternative targets (LRRK2, GBA) and next-generation delivery systems continues to advance the field[@bennett2024]. As delivery technologies improve and our understanding of PD pathogenesis deepens, ASO therapy may ultimately fulfill its promise as a disease-modifying treatment for Parkinson's disease.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Vercruysse, F., et al. (2023). Alpha-synuclein: A therapeutic target for Parkinson's disease?, Brain (2023)
Cooper, J. M., et al. (2022). Antisense oligonucleotide therapies for neurodegenerative diseases, Annual Review of Neuroscience (2022)
Bennett, C. F., et al. (2024). Antisense oligonucleotide therapeutics: From discovery to clinical translation, Nature Reviews Drug Discovery (2024)
[Dorsey, E. R., et al. (2023). Projected number of people with Parkinson disease in the most populous nations, 2005-2030, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/17202477/)
[Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease, The Lancet (2015)](https://pubmed.ncbi.nlm.nih.gov/25907222/)
[Spillantini, M. G., et al., (1997). Alpha-synuclein in Lewy bodies (1997)](https://pubmed.ncbi.nlm.nih.gov/9214510/)
[Brundin, P., & Melki, R. (2017). Pervasive prion-like propagation of protein aggregation in Parkinson's disease, Journal of Parkinson's Disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29125489/)
[Dauer, W., & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models, Neuron (2003)](https://pubmed.ncbi.nlm.nih.gov/12946879/)
[Devine, M. J., et al. (2011). Parkinson's disease associated with alpha-synuclein abnormalities, Brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21300670/)
[Federoff, M., et al. (2022). SNCA variants and reduced risk of Parkinson's disease, Neurology Genetics (2022)](https://pubmed.ncbi.nlm.nih.gov/35229065/)
[Burre, J., et al. (2015). Properties of native brain alpha-synuclein, Journal of Parkinson's Disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26485438/)
[Mollenhauer, B., et al. (2023). CSF biomarkers for alpha-synuclein pathology, Movement Disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37221247/)
[Southwell, A. L., et al. (2022). Antisense oligonucleotide therapy for neurodegenerative disease, Journal of Clinical Investigation (2022)](https://pubmed.ncbi.nlm.nih.gov/35020644/)
Biogen. (2022). Pipeline Update: BIIB101 for Parkinson's Disease, Biogen Pipeline (2022)
[McGrew, D., et al. (2020). IONIS-SNAS reduce alpha-synuclein in preclinical models, Molecular Therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32032669/)
Biogen. (2023). Biogen Discontinues BIIB101 Program for Parkinson's Disease, Investor Relations (2023)
[Unknown, Alessi, D. R., & Sammler, E. (2018). LRRK2 kinase in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29438011/)
[Sidransky, E., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease, The New England Journal of Medicine (2009)](https://pubmed.ncbi.nlm.nih.gov/19802147/)
Hammond, S. M., et al. (2021). Delivery of oligonucleotide therapeutics, Nature Reviews Drug Discovery (2021)
[Burgess, A., et al. (2024). Focused ultrasound for enhanced drug delivery to the brain, Theranostics (2024)](https://pubmed.ncbi.nlm.nih.gov/38328561/)
[Chi, X., et al. (2023). Long-term safety of ASO therapy in CNS diseases, Neurology and Therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37291234/)
FDA. (2023). Tofersen (Qalsody) FDA Approval Letter, FDA (2023)